Karen E. Thudium

Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality

M. Benjamin Hock, Karen E. Thudium, Montserrat Carrasco‐Triguero et al. · The AAPS Journal · 2014 · 93 citations · Full text

Immunohistochemistry, Medicine, Bioanalysis +12

Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Stephan A. Grupp, Theodore W. Laetsch, Jochen Buechner et al. · Blood · 2016 · 80 citations

Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas

Elizabeth Brém, Karen E. Thudium, Sapna Khubchandani et al. · British Journal of Haematology · 2011 · 52 citations · Full text

American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates

Karen E. Thudium, Sanela Bilic, Douglas D. Leipold et al. · mAbs · 2013 · 15 citations · Full text

Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).

Joerg Krueger, Henrique Bittencourt, Susana Rives et al. · Journal of Clinical Oncology · 2020 · 13 citations

B2001x Study, Cell Therapy, Immunodeficiencies +24